BeOne Medicines (BEIGF) Change in Inventory (2017 - 2026)

BeOne Medicines (BEIGF) has reported Change in Inventory for 10 consecutive years, with $47.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Inventory rose 2255.92% year-over-year to $47.2 million in Q2 2026; TTM through Jun 2026 was $218.3 million, a 342.21% increase from a year earlier, with the FY2025 full-year figure at $93.2 million, up 1.83% from the prior year.
• Change in Inventory was $47.2 million for Q2 2026 at BeOne Medicines, down from $71.8 million in the prior quarter.
• Over five years, Change in Inventory peaked at $88.6 million in Q4 2023 and troughed at -$23.8 million in Q3 2024.
• A 5-year average of $27.8 million and a median of $28.7 million in 2022 frame the typical range for Change in Inventory.
• Across the five-year window, Change in Inventory slumped 1842.71% in 2024 and jumped 2255.92% in 2026, its largest moves.
• Over 5 years, Change in Inventory stood at -$18.9 million in 2022, then jumped by 567.6% to $88.6 million in 2023, then slipped by 10.38% to $79.4 million in 2024, then decreased by 11.18% to $70.5 million in 2025, then plunged by 33.13% to $47.2 million in 2026.
• The last three Change in Inventory figures came in at $47.2 million (Q2 2026), $71.8 million (Q1 2026), and $70.5 million (Q4 2025), per Business Quant data.